OpenNashPodcasts

Topic

Jennifer Doudna

8 facts from 2 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.

2012

Jennifer Doudna helped develop CRISPR-Cas9 in 2012, a technology for precisely editing gene sequences in microorganisms, plants and animals.

“In 2012, she helped develop the breakthrough CRISPR-Cas9 technology, which enables the precise editing of gene sequences in microorganisms, plants, and animals.”

Speaker 3 · Ep. 119: Revolutionary, with UC Berkeley’s Jennifer Doudna, 0:00:24

2020

Doudna noted that two RNA-based COVID-19 vaccines looked highly effective in early studies within about a year of the virus becoming known.

“it's extraordinary to think that a year ago, we didn't even know about this virus, And now we have two different RNA-based vaccines that look highly effective in these early studies.”

Jennifer Doudna · Ep. 119: Revolutionary, with UC Berkeley’s Jennifer Doudna, 0:07:56

2020

Jennifer Doudna and Emmanuel Charpentier won the 2020 Nobel Prize in Chemistry for their CRISPR discovery.

“That discovery was made by the biochemist Jennifer Doudna, who, together with Emmanuel Charpentier, won the 2020 Nobel Prize in Chemistry.”

Bapu Jena · 72. What’s Stopping Us From Curing Rare Diseases?, 0:21:54

Undated

Doudna attributed the speed of the RNA vaccines to earlier academic and company research on RNA as a delivery vehicle that induces an immune response.

“Because of fundamental research that was done years ago in an academic setting and then later in companies to develop RNA as a delivery vehicle, and it's very effective in inducing an immune response.”

Jennifer Doudna · Ep. 119: Revolutionary, with UC Berkeley’s Jennifer Doudna, 0:07:56

Undated

Doudna described the idea of using genome editing to give people a protective gene that some lucky people inherit naturally, which protects against high cholesterol.

“The idea that one could use genome editing to give all of us a protective gene that is known to, and a few lucky people that inherit this naturally, have a protection against high cholesterol.”

Jennifer Doudna · Ep. 119: Revolutionary, with UC Berkeley’s Jennifer Doudna, 0:14:20

Undated

Doudna cautioned that correcting BRCA1 mutations to protect against breast cancer is not a year away.

“I don't want people to come away from this conversation thinking that we're a year away from being able to correct BRCA1 mutations in people that would give them protection against breast cancer, for example.”

Jennifer Doudna · Ep. 119: Revolutionary, with UC Berkeley’s Jennifer Doudna, 0:14:55

Undated

Doudna said a key need is to deploy CRISPR inside patients' bodies, called in situ, rather than editing cells in a lab and returning them.

“we do need to figure out how to deploy CRISPR in clinical settings to patients in situ, meaning in their body, without having to take cells out to do the editing in the lab and then put them back.”

Jennifer Doudna · Ep. 119: Revolutionary, with UC Berkeley’s Jennifer Doudna, 0:15:31

Episodes